Shopping Cart
- Remove All
 
Your shopping cart is currently empty
Laropiprant (MK-0524) is a potent and selective antagonist of prostaglandin D2 (PGD2) receptor (DP) such as and DP/DP1 receptor(Ki = 0.57 nM) and TP Receptor(Ki = 2.95 nM).

| Pack Size | Price | Availability | Quantity | 
|---|---|---|---|
| 1 mg | $32 | In Stock | |
| 5 mg | $79 | In Stock | |
| 10 mg | $115 | In Stock | |
| 25 mg | $231 | In Stock | |
| 50 mg | $355 | In Stock | |
| 100 mg | $507 | In Stock | |
| 200 mg | $693 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $87 | In Stock | 
| Description | Laropiprant (MK-0524) is a potent and selective antagonist of prostaglandin D2 (PGD2) receptor (DP) such as and DP/DP1 receptor(Ki = 0.57 nM) and TP Receptor(Ki = 2.95 nM).  | 
| Targets&IC50 |  DP/DP1 receptor:0.57 nM (ki), TP receptor:2.95 nM (ki)  | 
| In vitro | Laropiprant blocks DP receptor-dependent enhance in VASP phosphorylation, as well as inhibition of P-selectin expression, GPIIb/IIIa activation, and in vitro thrombus formation. Laropiprant antagonizes the increased platelet aggregation by TP and EP3 receptor activation. Laropiprant (1 μM) induces a significant inhibition of the aggregation but still counteracts the pronounced inhibition caused by PGD2 (30 nM) and BW245c (3 nM). Laropiprant (10 μM) and niacin inhibit in vitro thrombus formation[2].  | 
| Synonyms | MK-0524 | 
| Molecular Weight | 435.9 | 
| Formula | C21H19ClFNO4S | 
| Cas No. | 571170-77-9 | 
| Smiles | CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12 | 
| Relative Density. | 1.486 g/cm3 | 
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (229.41 mM), Sonication is recommended.   | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (9.18 mM), Sonication is recommended.  Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table  | ||||||||||||||||||||||||||||||||||||
DMSO 
  | ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.